Illumina, Inc. (ILMN)
| Market Cap | 12.38B |
| Revenue (ttm) | 4.37B |
| Net Income (ttm) | -1.22B |
| Shares Out | 158.26M |
| EPS (ttm) | -7.69 |
| PE Ratio | n/a |
| Forward PE | 17.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,123,663 |
| Open | 77.98 |
| Previous Close | 77.88 |
| Day's Range | 77.17 - 79.00 |
| 52-Week Range | 68.70 - 156.66 |
| Beta | 1.38 |
| Analysts | Buy |
| Price Target | 138.22 (+76.73%) |
| Earnings Date | May 8, 2025 |
About ILMN
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price forecast is $138.22, which is an increase of 76.73% from the latest price.
News
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and ac...
Target Validation for Genetic Targets Innovation Research Report 2025: 14,172 Deals Totaling $11.4 Billion - BGI biotech and illumina are Among the Leaders with Strong Portfolios
Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering.
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN...
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
SAN DIEGO , April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025. O...
Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders
Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing ...
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
Stephen MacMillan to retire from the Board SAN DIEGO , March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced cha...
Activist investor Keith Meister to join Illumina's board, WSJ reports
Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citin...
Activist Investor Meister to Join Illumina's Board
Keith Meister's hedge fund Corvex Management has a 2.5% stake in the gene-sequencing machine maker.
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program AGD members are using the population-level insights to u...
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments.
Illumina addresses recent developments in China
Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4.50 SAN DIEGO , March 10, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the Mar...
Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
Beijing banned imports of Illumina's gene-sequencing machines in response to U.S. tariffs.
Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year
Illumina leads as highest-scoring U.S. company in its industry SAN DIEGO , March 6, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, ...
US Firm Illumina Faces Setback as China Blocks Imports Amid Escalating Trade War
China has banned imports of genetic sequencers from Illumina Inc. ILMN, just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect.
Illumina Stock Drops as China Bans Imports of Gene-Sequencing Technology
Illumina was placed on China's list of ‘unreliable entities' in February.
China bans imports of Illumina's gene sequencers
China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina , just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods t...
Illumina, Inc. (ILMN) AGBT Investor Session Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN) AGBT Investor Session Conference February 25, 2025 11:00 AM ET Company Participants Salli Schwartz - Head of Investor Relations Jacob Thaysen - Chief Executive Officer St...
Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology
Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform Built on Illumin...
Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions
Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem with...
Illumina unveils first-of-its-kind spatial transcriptomics technology
Broad Institute to collaborate on flagship project tapping Illumina's new spatial technology At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning ...
Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference
SAN DIEGO , Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor sessio...
Trump's Cuts to Medical Research Are Hurting These Stocks
Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively.
Illumina: Regulatory Risk In China And Weaker Sales Rebound Mask A Solid Rebound Of Its Profitability
Illumina restored its profitability well: Free Cash Flow is reaching elevated levels. However, the placement of ILMN in China's unreliable entity list could have disruptive implications for its operat...
Illumina Analysts Slash Their Forecasts Following Q4 Results
Illumina, Inc. ILMN reported better-than-expected results for its fourth quarter on Thursday.